Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. - Wikidata - wikimedia - TriplyDB

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

http://www.wikidata.org/entity/Q35194552

about

Fucoidan, a sulfated polysaccharide, inhibits osteoclast differentiation and function by modulating RANKL signaling.Hormone replacement therapy in women with spinal cord injury - a survey with literature review.Rhus javanica Gall Extract Inhibits the Differentiation of Bone Marrow-Derived Osteoclasts and Ovariectomy-Induced Bone Loss.Nectandrin A Enhances the BMP-Induced Osteoblastic Differentiation and Mineralization by Activation of p38 MAPK-Smad Signaling Pathway.Effect of mechanical stretch on the proliferation and differentiation of BMSCs from ovariectomized rats.Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis.Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice.

P2860

Q34486957-AB35E3AD-C0B7-474C-9BFB-857E8926E8E0 Q35966781-34C440E0-97A0-4C27-AAF8-612FE5BC2E02 Q36995896-15EA5A9E-4B29-452B-B7DC-6B4389ECEF27 Q37297703-2CEE34CE-908F-4238-BCF6-AE447FA39A51 Q43777181-0516398A-5710-426C-BCF3-8DC813075037 Q46355750-EE90D134-79BA-4153-9002-15545C0A8B43 Q47138639-F3E86244-16EC-4DAF-B3AB-3682E295E523

P2860

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

http://www.wikidata.org/entity/Q35194552

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@ast

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@en

type

label

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@ast

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@en

prefLabel

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@ast

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@en

P1433

Q35194552-212ACA17-068F-4CF4-9EE6-A4E857A2909A

P1476

Q35194552-D1847369-310B-4FA1-9169-60746D959E6C

P2093

Q35194552-B9AAF8D6-413A-4F73-865B-6A0970897B6C

P2860

Q35194552-06E082FB-244B-414F-A527-9F4E07365336

Q35194552-09B322C1-A8E1-44A5-B904-EA5D7B2E6E20

Q35194552-148B04FB-A01A-4886-A58D-6B54C35B4292

Q35194552-1AAE1898-5575-4A41-84BA-9C496AA976C4

Q35194552-1C849B27-6E5B-4F1D-9CA2-ACB88A98C934

Q35194552-2459840E-A724-4C7F-93C5-F2B17D5C76B9

Q35194552-290B816B-1849-4047-8B5F-439E1D20A742

Q35194552-3690D008-FE69-43B3-B685-31CD8B19B6FD

Q35194552-36FE3991-36A1-4002-A894-71AAF8963262

Q35194552-37EFB4EE-6E5C-4C18-8176-2A9CE1F38E26

P304

Q35194552-AE529E67-1310-4D27-B6FE-2ADB285F917A

P31

Q35194552-B9884BEE-139D-48F2-B0A3-58B095B6A0F2

P356

Q35194552-F755572E-AEC6-4F2C-A58A-80E8DD8B7B6B

P407

Q35194552-0519E10F-B53F-4058-A03D-3BC5C1A0C5AC

P433

Q35194552-BF46BA93-9002-4063-A863-369C0CEB1E91

P478

Q35194552-FB41BE4B-6EE8-404A-8652-F6254F401613

P577

Q35194552-244CD46A-56C6-49AB-8DAB-B63E481EF2CC

P698

Q35194552-07E84C08-F9E2-47E1-BB71-AB766E74434F

P921

Q35194552-23CC1D3B-766D-4283-ABF6-FEBCABACF685

Q35194552-2FA08113-893A-4772-910F-A67EF6A657A7

P356

14740338.1.1.93

P1433

Expert Opinion on Drug Safety

P1476

Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

@en

P2093

Ian R Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.

P304

93-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.1.1.93

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12904164

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy